Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > CG Oncology phase 3 results impossible for TLT to beat?
View:
Post by cancerman24 on Jan 24, 2024 2:30pm

CG Oncology phase 3 results impossible for TLT to beat?

75.7% complete response rate at any time in phase 3. Announced Nov 30 2023 so may all know about it already.

Not bashing, just asking. 
Comment by Lesalpes29 on Jan 24, 2024 2:36pm
Hum.. a new one again!
Comment by DJDawg on Jan 24, 2024 3:21pm
Hi There was a previous discussion about CG Oncology and their results. Quite good except for the number of treatments. I previously took the clinical data and organized it to show results to date AND treatments needed to get there. See link for  the Creto AND keytrude protocol and results to date: https://postimg.cc/zyLb4GJp As you can appreciate the number of treatments is never ...more  
Comment by Oilminerdeluxe on Jan 24, 2024 3:32pm
Thanks, Dawg. 
Comment by cancerman24 on Jan 24, 2024 3:47pm
Thank you!
Comment by livermore2 on Jan 24, 2024 8:35pm
It's a combo treatment with Keytruda we are currently a standalone. This IPO may bring some eyes on us to show what kind of valuation a bladder treatment warrants.
Comment by Eoganacht on Jan 25, 2024 12:14am
They have a phase 3 standalone trial and a phase 2 combo with Keytruda.
Comment by livermore2 on Jan 25, 2024 8:23am
Thanks for clarifying that. Well looks like they have a hot IPO today which will be valued over 1B on the Nasdaq.https://www.morningstar.com/news/marketwatch/20240125223/cg-oncology-ipo-prices-above-range-and-boosts-share-count-in-bullish-move-ahead-of-trading
Comment by Gman620 on Jan 25, 2024 10:12am
Why should TLT get BTD with this out there?  Having lots of treatments and working with Keytruda is the exact sweet spot big pharma wants, hence their big money backers. Hard not to see this as  a dagger to TLT. As I've said before, if it has a high success rate, no one, especially patients,  cares about number of treatments. That's what pharma wants anyway.
Comment by Longholder99 on Jan 25, 2024 10:52am
The 75% of all people who dont match the genrtic profile and therefore can't take Keytruda, or don't want the laundry list of side effects immuno modifying drugs bring....they probably care.  
Comment by Rumpl3StiltSkin on Jan 25, 2024 11:53am
Exactly! 75% of ˜25% plus it is a pain to be on this compared to what TLT offers. Ruvidar doesn't have these restrictions.
Comment by Eoganacht on Jan 25, 2024 11:36am
For Theralase to get a BTD for Ruvidar PDT it needs to demonstrate a substantial improvement over an available therapy. CG0070 is not an available therapy either as a standalone or as a combo treatment with Keytruda, It does not have FDA approval. Therefore it has nothing to do with whether or not Ruvidar PDT gets a BTD or not. Ruvidar PDT needs to show a substantial improvennt over existing ...more  
Comment by DJDawg on Jan 25, 2024 11:56am
High success rate is tricky. Many patients have been through the long series of BCG instillations and then had that fail. Now to be offered another long series (weekly x 6 weeks, then 3 more at 3m, 6m, 9m and 12m) is a lot to take in. Many patients don't actually live near a urology care centre so there is lots of commuting to consider. In phase 1b, Ruvidar was used on 3 patients. 2 of them ...more  
Comment by Benedictus on Jan 25, 2024 11:43pm
The lease your life model appears to be the popular girl at the party. How else can you explain the FDA and uro-oncology community's love affair with the model and the enormous valuation disparity?  Aside from all the challenges patients experience in this wack-a-mole never ending treatment model, just how does a lease your life model get a pass with insurers? The issue is time and ...more  
Comment by enriquesuave on Jan 25, 2024 4:01pm
Incredible how CG is IPO'd at a Market Cap of $1.5 Billion US when they are at the same stage of trial as us.  Their Data is excellent and will be competition.  However it is a very treatment intensive solution.  With up to 15-21treatments in the 1st year plus 6 treatments in the 2nd year.So 27 treatments in 2 years.  Is still see this as a tie.  Although they have ...more  
Comment by wildbird1 on Jan 26, 2024 6:45am
COMPLETELY FALSE! In this link... https://clinicaltrials.gov/study/NCT04387461 Under '' Participation Criteria''...There is a blue box ''Show More'' Inside you will find the ''key Exclusion Criteria''. The two most interesting are ... 1) Clinically significant or active cardiac disease(older patients are more likely to have cardiac disease). 2 ...more  
Comment by Longholder99 on Jan 26, 2024 7:53am
Great post wildbird.  Haven't seen this pp of which some speak either.  I suppose if you keep saying it's going to rain until it eventually does you can claim you were right.  
Comment by Oilminerdeluxe on Jan 26, 2024 9:02am
Thanks wildbird
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250